Home / Technology & Devices (page 30)

Technology & Devices

Pfizer to Sell Infusion Business to ICU Medical in $1 Billion Deal

ICU Medical Inc. (NASDAQ:ICUI) and Pfizer Inc. (NYSE:PFE) today announced that they have entered into a definitive agreement under which ICU Medical will acquire all of Pfizer’s global infusion therapy business, Hospira Infusion Systems (HIS), for $1 billion in cash and stock. The Hospira Infusion Systems business includes IV pumps, solutions, and devices …

Read More »

QuintilesIMS: Merger Creates Leading Global Integrated Information and Technology-Enabled Healthcare Service Provider

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Quintiles IMS Holdings, Inc. (NYSE:Q) today announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational Holdings Inc. The merger of IMS Health, a leading global information and technology services company, and Quintiles, …

Read More »

Ambry Genetics Launches Comprehensive Multi-Gene Test for Hereditary Prostate Cancer

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ambry Genetics (Ambry) today announces that it has launched ProstateNext, a new 14-gene panel for hereditary prostate cancer. Ambry will feature it at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference taking place September 28-October 1 in Seattle, WA. This also coincides with Prostate …

Read More »

Adaptimmune and MD Anderson Partner to Advance Development of Immunotherapies for Multiple Cancers

PHILADELPHIA and HOUSTON, United States and OXFORD, United Kingdom, Sept. 26, 2016 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and The University of Texas MD Anderson Cancer Center announced today that they have entered into a multi-year strategic alliance designed to expedite …

Read More »

Third Rock Launches Relay Therapeutics to Create Breakthrough Medicines Based on Protein Motion

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Third Rock Ventures, LLC today announced the formation of Relay Therapeutics with $57 million in Series A financing, including participation from an affiliate of D. E. Shaw Research, LLC. Relay Therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion, with the aim of …

Read More »

Horizon and Fulcrum Therapeutics Partner for Novel CRISPR-Based Target Discovery

Cambridge, UK, 6 September 2016: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), the world leader in the application of gene editing technologies, today announced a new collaboration with Fulcrum Therapeutics Inc., (“Fulcrum”), a US-based firm founded in July 2016 by Third Rock Ventures. The collaboration will utilize Horizon’s world-leading CRISPR-based …

Read More »

Cell Medica and UCL Partner to Develop Modified T Cell Receptor Cancer Drugs

LONDON–(BUSINESS WIRE)–Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and infections, has signed a research collaboration with UCL (University College London) aiming to utilize UCL’s novel T cell receptor (TCR) technology to generate leading-edge modified TCR products for the treatment of cancer. The collaboration also …

Read More »

FDA Allows Marketing of First-of-Kind Computerized Cognitive Tests to Help Assess Cognitive Skills Post-Head Injury

The U.S. Food and Drug Administration today permitted marketing of two new devices to assess a patient’s cognitive function immediately after a suspected brain injury or concussion. The Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and ImPACT Pediatric are the first medical devices permitted for marketing that are intended to …

Read More »

First 3-D Map of Cell-Building Protein Linked to Cancer

Walter and Eliza Hall Institute researchers have revealed for the first time the three-dimensional molecular ‘map’ of a protein that has been pinpointed as a driver of many types of cancers. The unprecedented view of the protein doublecortin kinase like domain 1 (DCLK1) could provide clues to how it contributes …

Read More »

Walgreens Partners with HealthPrize Technologies for Game-Based Drug Adherence Platform

NORWALK, Conn., Aug. 16, 2016 /PRNewswire/ — HealthPrize Technologies today announced a collaboration with Walgreens through which the HealthPrize Action Engine® patient engagement and medication adherence platform will be offered through the drugstore chain’s website. The Walgreens program powered by HealthPrize will finish development later this month and will be …

Read More »